Attitudes toward deprescribing among adults with heart failure with preserved ejection fraction
- PMID: 33978239
- PMCID: PMC9198814
- DOI: 10.1111/jgs.17204
Attitudes toward deprescribing among adults with heart failure with preserved ejection fraction
Abstract
Background/objectives: Attitudes toward deprescribing could vary among subpopulations. We sought to understand patient attitudes toward deprescribing among patients with heart failure with preserved ejection fraction (HFpEF).
Design: Retrospective cohort study.
Setting: Academic medical center in New York City.
Participants: Consecutive patients with HFpEF seen in July 2018-December 2019 at a program dedicated to providing care to older adults with HFpEF.
Measurements: We assessed the prevalence of vulnerabilities outlined in the domain management approach for caring for patients with heart failure and examined data on patient attitudes toward having their medicines deprescribed via the revised Patient Attitudes Toward Deprescribing (rPATD).
Results: Among 134 patients with HFpEF, median age was 75 (interquartile range 69-82), 60.4% were women, and 35.8% were nonwhite. Almost all patients had polypharmacy (94.0%) and 56.0% had hyperpolypharmacy; multimorbidity (80.6%) and frailty (78.7%) were also common. Overall, 90.3% reported that they would be willing to have one or more of their medicines deprescribed if told it was possible by their doctors; and 26.9% reported that they would like to try stopping one of their medicines to see how they feel without it. Notably, 91.8% of patients reported that they would like to be involved in decisions about their medicines. In bivariate logistic regression, nonwhite participants were less likely to want to try stopping one of their medicines to see how they feel without it (odds ratio 0.25, 95% confidence interval [0.09-0.62], p = 0.005).
Conclusions: Patients with HFpEF contend with many vulnerabilities that could prompt consideration for deprescribing. Most patients with HFpEF were amenable to deprescribing. Race may be an important factor that impacts patient attitudes toward deprescribing.
Keywords: deprescribing; frailty; heart failure; polypharmacy.
© 2021 The American Geriatrics Society.
Conflict of interest statement
Figures
Similar articles
-
Attitude towards deprescribing and its association with frailty and complexity of medication regimen: A survey of older inpatients in a district health board in New Zealand.BMC Geriatr. 2023 Mar 23;23(1):166. doi: 10.1186/s12877-023-03878-2. BMC Geriatr. 2023. PMID: 36959598 Free PMC article.
-
Attitudes of Older Adults and Caregivers in Australia toward Deprescribing.J Am Geriatr Soc. 2019 Jun;67(6):1204-1210. doi: 10.1111/jgs.15804. Epub 2019 Feb 13. J Am Geriatr Soc. 2019. PMID: 30756387
-
What do older adults with multimorbidity and polypharmacy think about deprescribing? The LESS study - a primary care-based survey.BMC Geriatr. 2020 Oct 31;20(1):435. doi: 10.1186/s12877-020-01843-x. BMC Geriatr. 2020. PMID: 33129274 Free PMC article.
-
Differences in Older Patients' Attitudes Toward Deprescribing at Contextual and Individual Level.Front Public Health. 2022 Feb 11;10:795043. doi: 10.3389/fpubh.2022.795043. eCollection 2022. Front Public Health. 2022. PMID: 35223732 Free PMC article. Review.
-
Geriatric Domains in Patients with Heart Failure with Preserved Ejection Fraction.Cardiol Clin. 2022 Nov;40(4):517-532. doi: 10.1016/j.ccl.2022.06.006. Epub 2022 Sep 5. Cardiol Clin. 2022. PMID: 36210135 Free PMC article. Review.
Cited by
-
Deprescribing strategies in older patients with heart failure.Intern Emerg Med. 2024 Oct 15. doi: 10.1007/s11739-024-03791-5. Online ahead of print. Intern Emerg Med. 2024. PMID: 39406965 Review.
-
"Starting to think that way from the start": approaching deprescribing decision-making for people accessing palliative care - a qualitative exploration of healthcare professionals views.BMC Palliat Care. 2024 Sep 6;23(1):221. doi: 10.1186/s12904-024-01523-2. BMC Palliat Care. 2024. PMID: 39242514 Free PMC article.
-
Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape.Heart Fail Rev. 2024 May;29(3):631-662. doi: 10.1007/s10741-024-10385-y. Epub 2024 Feb 27. Heart Fail Rev. 2024. PMID: 38411769 Free PMC article. Review.
-
Unlocking Deprescribing Potential in Nursing Homes: Insights from a Focus Group Study with Healthcare Professionals.Drugs Aging. 2024 Mar;41(3):261-270. doi: 10.1007/s40266-023-01092-8. Epub 2024 Jan 29. Drugs Aging. 2024. PMID: 38285238 Free PMC article.
-
Older adults' attitudes towards deprescribing and medication changes: a longitudinal sub-study of a cluster randomised controlled trial.BMJ Open. 2024 Jan 10;14(1):e075325. doi: 10.1136/bmjopen-2023-075325. BMJ Open. 2024. PMID: 38199626 Free PMC article. Clinical Trial.
References
-
- Goyal P, Almarzooq ZI, Horn EM, et al. Characteristics of Hospitalizations for Heart Failure with Preserved Ejection Fraction. Am J Med. 2016;129(6):635 e615–626. - PubMed
-
- Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263–271. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
